Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: Comparison with metabolism in vivo

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 4, 2004, Pages 408-417

  Reder Hilz, B ^a   Ullrich, M ^a   Ringel, M ^b   Hewitt, N ^c   Utesch, D ^d   Oesch, F ^b   Hengstler, J G ^e  

^a ABBOTT GMBH AND CO KG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c In Vitro Technologies   (Germany)

^d MERCK KGAA   (Germany)

^e Rudolf Boehm Inst Pharmacol T   (Germany)

Author keywords

Cryopreservation; Hepatocytes; HPLC; In vitro; Metabolism; Propafenone; Verapamil

Indexed keywords

4' HYDROXYPROPAFENONE; 5 HYDROXYPROPAFENONE; CARBON 14; DRUG METABOLITE; GLUCURONIC ACID; N DESPROPYLPROPAFENONE; PROPAFENONE; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DOG; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO CULTURE; INCUBATION TIME; LIVER CELL; MALE; MOUSE; NONHUMAN; RAT; RAT STRAIN; ULTRAVIOLET RADIATION;

AGED; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CRYOPRESERVATION; DOGS; GLUCURONIDES; HEPATOCYTES; HUMANS; MICE; MIDDLE AGED; PROPAFENONE; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TIME FACTORS; VERAPAMIL;

EID: 2142694376     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0875-z     Document Type: Article

References (51)

1. Akrawi M, Rogiers V, Vandenberghe Y, Palmer CN, Vercruysse A, Shephard EA, Phillips IA (1993) Maintenance and induction in co-cultured rat hepatocytes of components of cytochrome P450-mediated monooxygenase. Biochem Pharmacol 45:1583-1591
2. Aldor E, Heeger H (1976) Propafenon - ein neues Antiarrhythmikum. Dtsch Med Wochensschr 101:1318-1322
3. Beerheide W, Mach MA von, Ringel M, Fleckenstein C, Schumann S, Renzing N, Hildebrandt A, Brenner W, Jensen O, Gebhard S, Reifenberg K, Bender J, Oesch F, Hengstler JG (2002) Downregulation of beta2-microglobulin in human cord blood somatic stem cells after transplantation into livers of SCID-mice: an escape mechanism of stem cells? Biochem Biophys Res Commun 294:1052-1063
4. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer H (1993) Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120-126
5. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M (1995) Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedberg's Arch Pharmacol 353:116-121
6. Cai WM, Chen B, Cai MH, Chen Y, Zhang YD (1999) The influence of CYP2D6 activity on the kinetics of propafenone enantionmers in Chinese subjects. Br J Clin Pharmacol 47:553-556
7. De Rienzo F, Fanelli F, Menziani MC, De Benedetti PG (2000) Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 14:96-116
8. DeSousa G, Florence N, Valles B, Coassolo P, Rahmani R (1995) Relationships between in vitro and in vivo biotransformation of drugs in humans and animals: pharmaco-toxicological consequences. Cell Biol Toxicol 11:147-153
9. Diener B, Utesch D, Beer N, Dürk H, Oesch F (1993) A method for the cryopreservation of the liver parenchymal cells for studies of xenobiotics. Cryobiology 30:116-127
10. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M (1999) Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 9:551-559
11. Dilger K, Meisel P, Hofmann U, Eichelbaum M (2000) Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome. Ther Drug Monit 22:366-368
12. 14C]verapamil in man. Drug Metab Dispos 7:145-148
13. Gebhardt R, Hengstler JG, Müller D, Glöckner R, Buenning P, Laube B, Schmelzer E, Martina Ullrich, Utesch D, Hewitt N, Ringel M, Reder-Hilz B, Bader A, Langsch A, Koose T, Burger HJ, Maas J, Oesch F (2003) New hepatocyte in vitro systems for drug metabolism: Metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures, Drug Metab Rev 35 145-213
14. Guillouzo A, Rialland L, Fautrel A, Guyomard C (1999) Survival and function of isolated hepatocytes after cryopreservation. Chem Biol Interact 121:7-16
15. 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9:41-55
16. Hege HG, Lietz H, Weymann J (1984b) Studies on the metabolism of propafenone: 2nd Comm.: studies on the biotransformation in the dog. Arzneimittelforschung 34:972-979
17. Hege HG, Lietz H, Weymann J (1986) Studies on the metabolism of propafenone, 3rd Comm.: isolation of the conjugated metabolites in the dog and identification using fast atom bombardment mass spectrometry. Arzneimittlelforschung 36:467-474
18. Hengstler JG, Van den Burg B, Steinberg P, Oesch F (1999) Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31:917-970
19. Hengstler JG, Utesch D, Steinberg P, Ringel M, Swales N, Biefang K, Platt KL, Diener B, Böttger T, Fischer T, Oesch F (2000a) Cryopreserved primary hepatocytes as an in vitro model for the evaluation of drug metabolism and enzyme induction. Drug Metab Rev 32:81-118
20. Hengstler JG, Ringel M, Biefang K, Hammel S, Milbert U, Gerl M, Klebach M, Diener B, Platt KL, Böttger T, Steinberg P, Oesch F (2000b) Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chem Biol Interact 125:51-73
21. Hengstler JG, Bolm-Audorff U, Faldum A, Janssen K, Reifenrath M, Gotte W, Jung D, Mayer-Popken O, Fuchs J, Gebhard S, Bienfait HG, Schlink K, Dietrich C, Faust D, Epe B, Oesch F (2003) Occupational exposure to heavy metals: DNA damage induction and DNA repair inhibition prove co-exposures to cadmium, cobalt and lead as more dangerous than hitherto expected. Carcinogenesis 24 63-73
22. Jenden DJ (1991) Difficulties in using animal data to predict pharmacological response in man. Neurosci Biobehav Rev 15:105-107
23. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NCO (2000) The pregnane x receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39
24. Karim N, Allmeling C, Hengstler JG, Haverich A, Bader A (2000) Diazepam metabolism and albumin secretion of porcine hepatocytes in collagen-sandwich after cryopreservation. Biotechnol Lett 22:1647-1652
25. Kocarek TA, Schuetz EG, Strom SC, Fischer RA, Guzlian PS (1995) Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 23:415-421
26. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28-33
27. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedberg's Arch Pharmacol 348:332-337
28. Lewis DFV, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS (1999) Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries. Drug Metab Drug Interact 15:1-49
29. Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, Rhamani R, De Sousas G (1999a) Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an internal expert panel. Chem Biol Interact 121:117-123
30. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM (1999b) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121:17-35
31. Mach MA von (2002) Primary biliary cirrhosis in classmates: co-incidence or enigmatic environmental influence? EXCLI J 1: 1-6
32. Mach MA von, Schlosser J, Weiland M, Feilen PJ, Ringel M, Hengstler JG, Weilemann LS, Beyer J, Kann P, Schneider S (2003a) Size of pancreatic islets of Langerhans: a key parameter for viability after cryopreservation. Acta Diabetol 40:123-129
33. Mach MA von, Schlosser J, Weiland M, Feilen PJ, Ringel M, Hengstler JG, Weilemann LS, Beyer J, Kann P, Schneider S (2003b) Cryopreservation of islets of Langerhans: optimization of protocols. EXCLI J 2:6-21
34. 14C]verapamil. J Med Chem 14:1178-1184
35. Nedelcheva V, Gut I (1994) P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24:1151-1175
36. Neidlein R, Wu M, Hege HG (1988) Synthesis of glucucronides of propafenone and 5-hydroxypropafenone by sepharose-bound uridine 5′-diphosphoglucuronyl-transferase. Arzneimittelforschung 38:1257-1262
37. Osterod M, Hollenbach S, Hengstler JG, Barnes DE, Lindahl T, Epe B (2001) Age-related and tissue-specific accumulation of oxidative DNA base damage in 7,8-dihydro-8-oxoguanine-DNA glycosylase (oggl) deficient mice. Carcinogenesis 22: 1459-1463
38. Osterod M, Larsen E, Le Page F, Hengstler JG, Van Der Horst GT, Boiteux S, Klungland A, Epe B (2002) A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous oxidative DNA base damage. Oncogene 28:8232-8239
39. Puech P, Gagnol JP (1990) Class IC drugs: propafenone and flecainide. Cardiovasc Ther 4:549-553
40. Ringel M, Oesch F, Bader A, Gerl M, Klebach M, Quint M, Tanner B, Dillenburg W, Böttger T, Hengstler JG (2002) Permissive and suppressive effects of dexamethasone on enzyme induction in hepatocyte cultures. Xenobiotica 32 653-666
41. Sandström R, Karlsson A, Knutson L, Lennernäs H (1998) Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 15:856-862
42. Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H (1999) The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 48:189-189
43. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10:605-612
44. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241
45. Steinberg P, Fischer T, Kinlies S, Biefang K, Oesch F, Böttger T, Bulitta C (1999) Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. Drug Metab Dispos 27:1415-1422
46. Swales NJ, Utesch D (1998) Metabolic activity of fresh and cryopreserved dog hepatocytes. Xenobiotica 28:937-948
47. Tan W, Li Q, McKay G, Semple HA (1998) Identification and determination of phase I metabolites of propafenone in rat liver perfusate. J Pharmacol Biomed Anal 16:991-1003
48. Tanner B, Beerheide W, Jensen O, Mach MA von, Ringel M, Fleckenstein C, Schumann S, Renzing N, Hildebrand A, Neubert S, Glawatz C, Hengstler JG (2003) Isolation and transplantation of human mesenchymal stem cells from cord blood. Geburtshilfe Frauenheilkunde 63:1040-1046
49. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. J Clin Pharmacol 47: 545-552
50. Walle T, Oatis JE Jr, Walle UK, Knapp DR (1982) New ring hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos 10:122-127
51. Watson PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036